EarningsNet revenues in 3Q25 exceed expectations; raises 2025 revenue guidance; pipeline on track.
Patent ProtectionBoth GR and HD are supported by utility patent filings that may extend potential exclusivity through 2044, preserving long-term value beyond the expected 2030 loss of exclusivity for WAKIX.
Patient GrowthWAKIX achieved the highest ever quarterly increase in average number of patients of approximately 500, reaching 8,100 average patients in 3Q25.